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mitral replacement. To assess how experience may impact
the efﬁcacy of mitral repair on patients with increasing
complexity, we examined 941 consecutive patients who
underwent mitral valve repair from July 1992 to January
2000. METHODS: All patients underwent primary
mitral repair for regurgitation. Of the 941 patients, 750
had their operations between July 1992 and December
1998 (A), and 191 between January 1999 and January
2000 (B). Outcomes were analyzed for incidences of STS
co-morbid criteria and concomitant cardiac procedures
(valvular, arch, or CABG) performed during the study
periods. RESULTS: For the 941 patients, 530 (56%) were
male, patient age was 62 ± 13.3 years (range 20–88).
Group A included 204/750 with comorbidities (27.2%)
vs. 176/191 (92%) in Group B (p < 0.0001). Overall 
incidence of concomitant procedures in the 2 groups was
similar [58% A, 57% B (p = NS)]. Cross clamp times were
reduced from 104.9 ± 12.5 min in Group A to 84.9 ± 10.4
min in Group B (p < 0.0001). There were no differences
in atrial ﬁbrillation between groups (27.6% A, 28.3% B).
There were a total of 53 30-day mortalities (5.6%), with
a trend towards reduced mortality in Group B [6.1%
Group A, 3.7% Group B (p = 0.19)]. Average LOS
decreased from 12.2 ± 14.9 days in Group A to 8.7 ± 8.5
days in Group B (p = 0.02). CONCLUSIONS: Mitral
valve repair remains a safe and effective treatment for
patients with mitral regurgitation including those with
comorbid conditions and those requiring concomitant
cardiac procedures. As experience is gained with repara-
tive techniques, surgeons may be more willing to safely
apply them to an increasingly complex patient 
population.
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OBJECTIVES: This study sets out to explore the adher-
ence to British Hypertension Guidelines in choosing ﬁrst-
line treatment for blood pressure by general practitioners
(GPs) in the UK. These currently recommend thiazide
diuretics as the preferred choice and beta-blockers as 
an alternative initial treatment for most patients.
METHODS: The data on choice of blood pressure treat-
ment recorded at ﬁrst diagnosis of hypertension were
obtained from a UK GP computer database, IMS Disease
Analyzer—Mediplus. The records covered the 1-year
period March 2002 to February 2003. The database
holds the records of 564GPs and 948,958 registered
patients. RESULTS: Of 8,540 patients with at least three
months history on the database and a new diagnosis of
hypertension within the year of analysis, initial treatment
was as follows: 36.5% thiazide diuretic; 22.4% beta-
blocker; 17.8% ACE inhibitor; 10.1% calcium channel
blocker; 4.0% angiotensin-2-receptor antagonist; 2.1%
alpha-blocker. Of those, 16.4% were not started imme-
diately on antihypertensive therapy. Of those that did,
4.6% received ﬁrst treatment as a combination of two
drugs (hence the total ﬁgures do not add up to 100%).
CONCLUSIONS: This study suggests that ﬁrst-line treat-
ment is often using a drug that is not in accord with
current National policy as only 58.9% were started on
recommended ﬁrst-line therapy. Choices from other drug
classes tend to be more expensive, and there is less evi-
dence of beneﬁt. In particular the 4.6% starting treatment
with combination therapy appears at odds with the policy
to start with a single agent. Co-morbidity such as diabetes
or bladder outﬂow obstruction may explain the choice of
other agents; for example angiotensin-inhibiting drugs in
diabetes, but the prevalence of these conditions is not suf-
ﬁcient to explain this variation from the guidelines. This
choice of drugs may reﬂect heavy marketing of these
newer products rather than evidence-based medicine.
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OBJECTIVES: To demonstrate the feasibility and pa-
tient acceptance of a health care intervention using 
the patient’s mobile phone (HTA-Alert Study), and to
describe the pattern of use of this tool in the usual clini-
cal practice (INFONET Program) in hypertensive (HT)
patients. METHODS: 1) HTA-Alert Study: 20 primary
care investigators were randomized to Control (CG) or
Intervention (IG) group. Investigators of IG registered
their patients in a free SMS service. These patients
received two short-messages per week, during 24 weeks.
Messages addressed issues related with compliance and
health habits. 2) INFONET Program: 40 Hypertension
Units (UHTA) asked patients to enter periodically blood
pressure into a private web site, where physicians had
access to data. Physicians were asked to send free-text
SMSs to the patient mobile phone via web application at
their own convenience. RESULTS: 1) HTA-Alert: 33
Patients CG and 34IG were studied. There was a relevant
reduction in weight (from 80.47 ± 9.76kg to 76.84 ±
8.92; p < 0.001) in the IG. Hypertension was reduced in
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both groups, but IG patients showed an earlier control
(61.8% control in IG vs 36.4% in CG at 12 weeks; p =
0.038). 2) INFONET Program: The ﬁrst 250 SMS were
analysed. Percentages of SMS sent by physicians were:
support (50.3%), Therapeutic compliance (2.7%),
Asking for data (29.5%), Scheduling visits to surgery
(6.0%), Modifying medication (1.6%), Others (9.9%).
The most frequent scheduling was one SMS every 12
days. CONCLUSIONS: In the usual practice (INFONET
Program), physicians use the SMS system in a different
way than predicted (HTA-Alert). They tend to give
support and to ask for data, instead of addressing com-
pliance and life-habits messages. Frequency of messages
was also lower. The use of SMSs seems to be a useful tool
for educational programs, and it would be convenient to
explore in more detail its effectiveness in health outcomes.
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OBJECTIVES: To establish the effect of a pharmaceuti-
cal care program on compliance and persistence with
once-daily atorvastatine treatment in patients with ele-
vated cholesterol levels. METHODS: An open-label,
prospective controlled trial of 1-year duration was con-
ducted in Belgium, stratiﬁed by language region. A French
speaking and a Flemish speaking region were randomized
to a Measurement Guided Medication Management
(MGMM) intervention consisting of review by the
patients’ pharmacist of the electronically compiled dosing
history, a “beep-card” that reminds patient of the dosing
time and educational reminders. The control group
received care as usual, also stratiﬁed between the 2
regions. Compliance was measured in all patients using
the Medication Event Monitoring System (MEMS®,
AARDEX, Switzerland), deﬁned as the % doses taken as
prescribed (once-daily). Nonpersistence was deﬁned as
the % of patients who stopped using atorvastatine before
the end of the study. Because of the skewed nature of
compliance data, statistical reporting includes medians,
25–75% interquartile ranges, and non-parametric tests.
RESULTS: A total of 393 patients were included: inter-
vention group: n = 194, control group: n = 199. After 1-
year follow-up and stratiﬁcation by region, the median %
of doses taken as prescribed (25% quartile–75% quartile)
was 96.1 (92.7–98.2) in the intervention group versus
89.9 (77.1–95.6) in the control group (p < 0.0001). Other
compliance variables showed similar results % prescribed
doses taken: 98.9 (96.3–100.3) vs 95.2 (83.0–98.9), p <
0.001, % doses within prescribed interval ±25%: 92.8
(85.9–95.9) vs 84.4 (63.0–92.5), p < 0.001 and Thera-
peutic Coverage: 96.1 (92.9–97.8) vs 93.6 (84.6–96.6), 
p < 0.001. Persistence was signiﬁcantly better in the inter-
vention group: 87.1% vs 76.9% in the control group 
(p = 0.02). Explanatory analysis showed that the Flemish
patient group and an elevated cardiovascular risk score
were signiﬁcantly related to better compliance and per-
sistence. CONCLUSIONS: Measurement Guided Med-
ication Management improved patient compliance and
persistence with atorvastatine.
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OBJECTIVE: Troponin T levels (TnT) predict hard
ischemic events and prognosis in patients (p) with unsta-
ble angina (UA) or non ST-segment elevation myocardial
infarction (NSTEMI). There are no reports on their
ability to predict the development of heart failure (HF) in
that population. METHODS: In order to determine the
ability of TnT to predict the incidence of NYHA class III
or IV HF along three months after an episode of unsta-
ble UA or NSTEMI, TnT levels were measured to 352 p
between the ﬁfth and 24th hour from hospital admission
due to an acute episode attributable to such diagnosis,
being 231 men and 121 women, mean age 67.6 years
(range 20 to 88). Personal or phone interview of patients
or relatives were obtained three months after the acute
episode looking for signs or symptoms of advanced heart
failure. RESULTS: TnT levels were higher than or equal
to 0.1ng/ml in 135p (TnT+ group) and less than 
0.1ng/ml in the other 217p (TnT- group). Both groups
were comparable in age (69 vs 66) and slightly different
in proportion of women (42% vs 32%). Three patients
died after episodes of class IV HF and all three pertained
to the TnT+ group. Odds ratios (OR) and their 95% con-
ﬁdence intervals (Cl) for the development of class III or
IV HF are reﬂected in the table. CONCLUSIONS:
Patients admitted with the diagnosis of unstable angina
or non ST-segment elevation myocardial infarction have
much more episodes of advanced heart failure in the fol-
lowing three months when Troponin T levels are elevated
in the ﬁrst 24 hours of the acute ischemic episode. TnT+
TnT- n(%) n(%) OR 95%CI p NYHA III/IV 11(8.9)
5(2.4) 3.85 1.3–11.3 < 0.03 NYHA IV 7(5.5) 2(0.9) 5.88
1.2–28.7 < 0.05.
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